phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
Published 13 years ago • 1.4K plays • Length 9:52Download video MP4
Download video MP3
Similar videos
-
3:18
phase 3 axis 1032 trial discussion with brian i. rini, md
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
6:53
goals in previously treated advanced renal cell carcinoma
-
1:03
dr. hutson discusses the phase iii atlas study in rcc
-
4:39
avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
2:32
avelumab plus axitinib improves survival in advanced renal-cell carcinoma patients
-
0:44
real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc
-
6:01
dart study: phase 2 study of dalantercept plus axitinib in advanced clear cell rcc
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
3:41
tide-a: avelumab and intermittent axitinib in metastatic renal cell carcinoma
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:38
dr. choueiri on avelumab plus axitinib in mrcc
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma